ISAL 2019 | Triplebodies for AML: origin, rationale & development

Georg Fey

Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the origin and rationale behind triplebodies, as well as giving an overview of triplebody agents in development. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video